According to Enanta Pharmaceuticals
's latest financial reports the company has $0.33 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-09-30 | $0.36 B | 48.42% |
2022-09-30 | $0.24 B | 2.14% |
2021-09-30 | $0.24 B | -36.89% |
2020-09-30 | $0.38 B | 15.34% |
2019-09-30 | $0.33 B | 8.59% |
2018-09-30 | $0.30 B | 38.03% |
2017-09-30 | $0.22 B | 6.47% |
2016-09-30 | $0.21 B | 44.68% |
2015-09-30 | $0.14 B | 59.98% |
2014-09-30 | $90.76 M | -10.56% |
2013-09-30 | $0.10 B | 131.89% |
2012-09-30 | $43.76 M | 87.59% |
2011-09-30 | $23.32 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $22.92 B | 6,700.22% | ๐บ๐ธ USA |
Novartis NVS | $9.69 B | 2,775.27% | ๐จ๐ญ Switzerland |
AbbVie ABBV | $12.81 B | 3,701.26% | ๐บ๐ธ USA |
Vertex Pharmaceuticals VRTX | $11.21 B | 3,227.38% | ๐บ๐ธ USA |
Merck MRK | $7.09 B | 2,003.81% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $9.67 B | 2,768.15% | ๐บ๐ธ USA |